Figure 1

Identification of dMSCs derived from patients with PE and healthy donors. A: Morphology of dMSCs from healthy pregnant women within 1 week of culture; B: Morphology of dMSCs from patients with PE within 1 week of culture; C: Flow cytometric characterization of dMSCs isolated from healthy pregnant woman during passage 3. Expression of surface antigens CD105, CD73, CD90, CD29, CD44, HLA-DR, CD19, CD11b, CD106, CD45, CD14, CD34, and CD31 was detected using flow cytometry. The percentage of each positive marker is shown. The percentages are shown as mean ± SE from five healthy pregnant women; D: Flow cytometric characterization of dMSCs isolated from patient with PE during passage 3. Expression of surface antigens CD105, CD73, CD90, CD29, CD44, HLA-DR, CD19, CD11b, CD106, CD45, CD14, CD34, and CD31 was detected using flow cytometry. The percentages are shown as mean ± SE from five patients with PE. dMSC, decidua-derived mesenchymal stem cell; PE, pre-eclampsia; SE, standard error.